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Abstract
Previous work by our group has shown the pro-differentiating effects of apotransferrin 
(aTf) on oligodendroglial cells in vivo and in vitro. Further studies showed the 
remyelinating effect of aTf in animal demyelination models such as hypoxia/ischemia, 
where the intranasal administration of human aTf provided brain neuroprotection and 
reduced white matter damage, neuronal loss and astrogliosis in different brain regions.
These data led us to search for a less invasive and controlled technique to deliver aTf to 
the CNS. To such end, we isolated extracellular vesicles (EVs) from human and mouse 
plasma and different neuron and glia conditioned media and characterized them based 
on their quality, quantity, identity and structural integrity by Western blot, dynamic light 
scattering and scanning electron microscopy. All sources yielded highly pure vesicles 
whose size and structures were in keeping with previous literary evidence. Given that, 
remarkably, EVs from all sources analyzed contained Tf receptor 1 (TfR1) in their 
composition, we employed two passive cargo-loading strategies which rendered 
successful EV loading with aTf, specifically through binding to TfR1.
These results unveil EVs as potential nanovehicles of aTf to be delivered into the CNS 
parenchyma, and pave the way for further studies into their possible clinical application 
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1. Introduction
Extracellular vesicles (EVs) are lipid bilayer-enclosed structures originated from the 
intracellular endocytic trafficking pathway or from the plasma membrane which are 
released into the extracellular space by a variety of cells (György et al., 2011; Harding et 
al., 1983; Pan et al., 1985). The lipid composition of EVs reveals enrichment in cholesterol, 
sphingomyelin and ganglioside GM3 levels (Wubbolts et al., 2003; Skotland et al., 2017). 
Furthermore, their membranes contain tetraspanin proteins, including CD63 ‒a protein 
accumulating in multivesicular bodies‒, CD9/CD81 ‒mainly at the plasma membrane‒, and 
endosome membrane proteins flotillin and ALIX, which have been used as EV markers 
(Park et al., 2010; Kowal et al., 2016). EVs can be secreted by most cell types in vitro and 
are detectable in different biological fluids such as blood (Harding et al., 1984; Sanz-Rubio 
et al., 2018), cerebrospinal fluid (CSF) (Soares Martins et al., 2018), breast milk (Zhou et 
al., 2011), urine (Keri et al., 2018; Hildonen et al., 2016) and plasma (Caby et al., 2005).
From a physiological point of view, EV secretion was initially postulated as a mechanism 
through which cells eliminate unnecessary proteins (Harding et al., 1983; Pan et al., 1985). 
However, studies indicate that EVs are actually involved in long-distance intercellular 
communication, facilitating the transfer of functional proteins, mRNAs and miRNAs for 
subsequent protein expression in target cells (Skog et al., 2008; Valadi 2007). Protection by 
a lipid bilayer lends EVs stability in the bloodstream and keeps the payload safe from the 
immune system. In addition, EV lipid membranes can help them bypass natural barriers 
such as the blood brain barrier (BBB) (Rajendran et al 2014; Basso et al., 2016). 
Altogether, these characteristics make EVs a valuable delivery system for pharmacological 
substances to address different central nervous system (CNS) diseases (Caruso Bavisotto et 
al., 2019).
EV isolation from biological fluids with good recovery and free of protein or lipoprotein 
contamination remains to be optimized. Although differential centrifugation and density-
gradient ultracentrifugation are the most widely applied methods so far, protein aggregates 
are generated at high speed, and vesicles may thus clump (György B et al., 2011). Isolation 
of EVs is further hindered by plasma viscosity and density and by the presence of 
lipoproteins, therefore requiring longer ultracentrifugation times and higher speeds, which 
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Multiple alternative approaches have been developed to tackle these obstacles, among 
which the use of size exclusion chromatography (SEC) columns emerges as a suitable 
method to obtain clean EVs from supernatants or plasma. SEC is hence now recognized as 
the best method for separation of EVs from most, but not all, serum proteins (Hong et al 
2016).
Apotransferrin (aTf) is the main Fe3+ transporter in the organism and is mostly expressed in 
the liver. In the CNS, aTf is produced by oligodendrocytes and is vital for normal brain 
development. Our group has previously demonstrated the pro-differentiating effects of aTf 
in vivo (Escobar Cabrera et al., 1994; Escobar Cabrera et al., 1997; Marta et al., 2000) as 
well as in vitro (Paez et al., 2002). We have also reported that a single intracranial injection 
of aTf stimulates remyelination after cuprizone-induced demyelination (Adamo et al., 
2006) and prevents hypomyelination produced by iron deficiency (Rosato-Siri et al., 2010). 
Furthermore, using a hypoxic ischemic model in rats, we have shown that aTf injected 
intracranially reduces white matter injury (Guardia Clausi et al., 2010), while human aTf 
administered intranasally provides neuroprotection to neonate animals (Guardia Clausi et 
al., 2012).
The use of EVs with a clearly defined active therapeutic cargo such as aTf entails the need 
of a surface marker to ensure targeting at recipient cells. However, EV isolation as nano-
vehicles and their targeting at specific cell types affected in the CNS remain a challenge. 
Although shown to stimulate remyelination in animal models, intracerebral administration 
of aTf might not be adequate for clinical treatments. For these reasons, intranasal 
administration might be regarded as a highly promising non-invasive route for the treatment 
of chronic CNS disease, with several studies underscoring the potential of loaded EVs 
(Zhang et al., 2011; Haney et al., 2015; Long et al., 2017). Moreover, aTf encapsulation in 
EVs reduces potential immunogenicity, prevents its degradation by proteases and allows it 
to cross the BBB without serious systemic side effects. Therefore, the development of a 
minimally invasive technique to intranasally administer aTf-loaded EVs targeted at 
oligodendrocytes might prove to have clinical significance.
In this context, our work has focused on the isolation of EVs from plasma and different 
conditioned media, with special emphasis on those of human plasma. EV preparations were 
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receptor 1 (TfR1) in EVs isolated from different sources and the binding of aTf to its 
receptor make EVs suitable vehicles for aTf and paves the way for their use as nanocarriers 
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2. Materials and Methods
2.1. Ethics statement
Experiments complied with the guidelines for animal use and care of Facultad de Farmacia 
y Bioquímica, Universidad de Buenos Aires, approved by Council Directive Res.250/2014. 
No randomization methods were applied. No blinding was performed. This study was not 
pre-registered. Sample size was determined using literary evidence in the field (El-
Andaloussi et al., 2012; Haney et al., 2015; Böing et al., 2014; Théry et al., 2006)
2.2. Materials and reagents
Human aTf, poly-L-lysine and Sepharose CL-2B were obtained from Sigma-Aldrich (St 
Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM)/F12 and human 
transferrin conjugated to Texas red (Tf-TR) were purchased from Life Technologies 
(Buenos Aires, Argentina). Fetal calf serum (FCS) was obtained from Natocor (Córdoba, 
Argentina). Twelve mL cartridges were purchased from Applied Separations (Allentown, 
PA, USA), PVDF transfer membranes were from Millipore (Temecula, CA, USA), while 
ECL Plus Western Blotting Detection reagents were purchased from GE Healthcare 
(Buckinghamshire, UK). Antibodies used were as follows: mouse anti-Alix (RRID: 
AB_10899268), mouse anti-CD63 (ab213090), mouse anti-CD63 (ab193349) and rabbit 
anti-Calnexin (CNX) (RRID: AB_1310022) were purchased from Abcam (Cambridge, UK) 
chicken anti- seroTf (RRID: AB_1081485) was from Genetex (Irvine, California) while 
mouse anti-TFR1 (RRID: AB_86623) was obtained from Thermo Fischer Scientific (San 
Jose, CA, USA). Human anti Tf (RRID: AB_2287232) was from ICN Biomedicals 
(Cappel, Aurora, Ohio), Horseradish peroxidase-conjugated secondary antibodies used for 
immunoblotting were obtained from Jackson Immuno Research Laboratories (West Grove, 
PA, USA). All other chemicals were analytical grade reagents.
2.3. Cells and plasma EVs sources
The mouse cell line Neuro-2A (N2a) derived from a spontaneous neuroblastoma in A/J 
mice (ATCC; CCL-131), and the rat oligodendroglioma OLN-93 cell line (a generous gift 
from Dr. C. Richter-Landsberg (Richter-Landsberg et al., 1995)), neither listed as a 
commonly misidentified cell line by the International Cell Line Authentication Committee, 
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streptomycin and 5 U/mL penicillin at 37 °C in a humidified atmosphere containing 5% 
CO2. The medium was replaced every 2 or 3 days until reaching 70% confluence.
The oligodendrocyte conditionally immortalized cell line N20.1, kindly provided by Dr. 
A.T. Campagnoni (Verity et al., 1993) and not listed as a commonly misidentified cell line 
by the International Cell Line Authentication Committee, was grown to confluence in 
DMEM/F12 with 10% FCS at 34 °C (permissive temperature). The medium was replaced 
by DMEM/F12 with 1% FCS and the temperature shifted to 39 °C (non-permissive 
temperature) for 7 days. Cells were maintained up to 8 passages, cryopreserved regularly 
and authenticated according to ATTC recommended tests, through morphological 
observation on an optical microscope and Hoechst assays to control mycoplasma 
contamination.
Primary cultures of astrocytes from newborn P0-P3 Wistar rats (Jackson Laboratory, RRID: 
RGD_13508588) were performed according to McCarthy and de Vellis (McCarthy et al., 
1980). Animals were decapitated with scissors and, after the removal of the meningeal 
membranes, cerebral hemispheres were mechanically dissociated by gentle repetitive 
pipetting in a mixture of DMEM/F12 (v/v) supplemented with 10% FCS, 5 mg/mL 
streptomycin and 5 U/mL penicillin. The cell suspensions were seeded in poly-L-lysine-
coated 75 cm2 tissue culture flasks and incubated at 37 °C in 5% CO2, with medium 
changes every 3 days. After 14 days in culture and once cells reached confluence, the 
microglial subpopulation was discarded after a first shake at 140 rpm/min during 1 h. The 
remaining culture was then shaken overnight at 250 rpm at 37 °C, the suspended cells were 
discarded, and the remaining astrocytes were kept in DMEM/F12 with 1% FCS.
Human and mouse plasma were obtained from blood samples from healthy donors recruited 
from the lab personnel (n=5; both genders; age: 25-35 years; BMI: 24 – 33), or mouse (25-
40 g; 45–50 days old) obtained from Jackson Laboratory (RRID: MGI:5656552), and 
collected into tubes containing citrate dextrose solution (BD Biosciences Pharmingen, San 
Diego, CA, USA). Plasma was obtained by two centrifugation cycles at 3,000 x g for 10 
min at 4 ºC, keeping in both cases the supernatants. For plasma EV isolation a total of 20 
adult mice were used. For primary culture 10 P0-P3 rats were used.
Animals were maintained in transparent plastic cages with a maximum of 5 animals per 
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and automated water delivery systems, were checked frequently to ensure appropriate 
maintenance, cleanliness and operation.
2.4. Isolation of EVs from blood plasma with size-exclusion chromatography (SEC)
SEC was performed as described previously (Böing et al., 2014). Two mL of human or 
mouse plasma were loaded into gravity-eluted columns of 12 mL cartridges containing 
Sepharose CL-2B matrix and fractions were eluted with degassed PBS:citrate 0.32%. The 
first 4 fractions of 1 mL were collected, pooled and ultracentrifuged at 100,000 x g for 70 
min at 4 ºC. The resulting pellets were lysed with RIPA extraction buffer (NaCl 150 mM, 
EDTA 5 mM, Tris 50 mM, NP-40 1%, SDS 0.1%) supplemented with a protease inhibitor 
cocktail for 5 min on ice or in PBS, depending on the assay. Additionally, a dilution of 
plasma sample in RIPA buffer was prepared at the same time and used in parallel with EVs 
as control for immunoblot analysis.
2.5. Isolation of EVs from conditioned media by differential centrifugation
Following the different cell culture conditions previously described, N2a, N20.1, OLN-93 
cells and astrocytes from primary cultures were grown to 70 % confluence, washed twice 
with PBS and replaced with serum-free medium for 24-72 h. The conditioned media were 
collected and centrifuged during 10 min at 300 × g in order to remove the remaining cells. 
The supernatants were then subjected to 2,000 × g centrifugation to remove dead cells. The 
resulting supernatants were collected and centrifuged at 10,000 × g for 30 min at 4 ºC in 
order to pellet the cell debris and organelles. Finally, the supernatants were again subjected 
to high speed centrifugation at 100,000 x g for 70 min at 4 ºC to pellet EVs. The pellet was 
washed with 1 mL PBS to eliminate the contaminating proteins and ultracentrifuged again 
at 100,000 x g for 70 min at 4 ºC. In all cases the resulting pellet were lysed with RIPA 
extraction buffer supplemented with a protease inhibitor cocktail for 5 min on ice or in 
sterile PBS, depending on the assay. Additionally, cellular lysates were prepared at the 
same time and used in parallel with EVs as control for immunoblot analysis.
2.6. Immunoblot analysis
EVs obtained from conditioned media were harvested in 100 μL of ice cold lysis buffer (20 
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PMSF, 1 mmol/L aprotinin, 0.1 mmol/L sodium vanadate, and 20 mmol/L of sodium 
fluoride). Protein content in EV samples and cell lysates was determined by Pierce BCA 
Protein Assay Kit (Life Technologies), and the samples were adjusted with loading buffer 
containing 2% sodium dodecyl sulfate (SDS), 5% glycerol, 5% β-mercaptoethanol and 
0.01% bromophenol blue, boiled for 5 min. Aliquots containing 20 μg - 40 μg protein were 
resolved by 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
onto PVDF membranes. Membranes were blocked with 5% non-fat dried milk in 0.1% 
Tween 20 in TBS for 1 h at room temperature and incubated with an appropriate primary 
antibody overnight at 4 °C (CD63 1:600; Alix 1:1000; TfR1 1:1000; Tf 1:1000; CNX 
1:1000). After being washed 3 times for 10 min with TBS Tween 0.1%, membranes were 
incubated with the corresponding secondary antibodies (1:20000), and bands were 
visualized by Pierce™ ECL Western Blotting Substrate (Thermofisher, Waltham, MA, 
USA).
2.7. Size and size distribution analysis
The average size (Z-average), the hydrodynamic diameter (Dh), the size distribution 
(polydispersity index, PDI) and zeta potential (Z-potential) of different EV sources were 
assayed by dynamic light scattering (DLS, Zetasizer Nano-ZS, Malvern Instruments, 
Worcestershire, UK) at a scattering angle of 173º. The Nano-ZS contains a 4 mW He-Ne laser 
operating at a wavelength of 633 nm, a digital correlator ZEN3600 and Non-Invasive Back 
Scatter (NIBS®) technology. For the preparation of each EV sample, 1 mL plasma was 
isolated and resuspended in 10 μL of the original fresh sample and then diluted to 1000 μL of 
final volume using PBS (1:100). All the samples were analyzed at 4 and 25 ºC. Refractive 
index (RI) was 1.48 and viscosities between 1.568 and 1.572 cP (4 ºC) and 0.8866 and 0.8885 
cP (25 ºC). Results are expressed as mean ± S.D. of three independent samples prepared in 
identical conditions. Data for each single specimen were the result of at least six runs.
2.8. Scanning electron microscopy (SEM)
After the first ultracentrifugation step, the pellets of all samples were fixed in 50 μl 
paraformaldehyde (PFA) 4% for 15 min at 4 ºC. The solution was then washed with 1 mL 
Milli-Q water and ultracentrifuged at 100,000 x g for 70 min at 4 ºC, and the resulting pellet 
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substrate, dried, metalized and observed with a Zeiss Supra Electron microscope. Six fields 
per experimental n were chosen randomly and EV size was determined using ImageJ 
software, first calculating the area of each individual EV to obtain the diameter.
2.9. Loading of aTf into EVs
Molecules can be incorporated into EVs using different approaches that result in different 
loading efficiency and molecule stability (Luan et al., 2017).
2.9.1. Passive loading of aTf into human plasma EVs
For aTf loading into human plasma EVs, we first verified the presence of TfR1 in EVs. Upon 
detection of TfR1, EVs isolated from 2 mL of human plasma isolated by SEC were incubated 
with 100 µg/mL aTf overnight at room temperature and loading efficiency was evaluated by 
Western blot and fluorometry.
2.9.2. Passive loading of aTf into OLN93 EVs
To obtain aTf-loaded EVs, when the cells reached 70% confluence, the medium was depleted 
from FCS and cells were treated with either vehicle or 100 µg/mL of aTf for 30 min, which is 
the time when Tf reaches its maximum cytoplasmic concentration (Böing et al., 2013). 
Subsequently, 48-72 h later, culture media were collected and EVs were isolated by 
differential centrifugation and ultracentrifugation methods.
2.10. Ligand-binding assays of EV-TfR1-Tf
2.10.1 Competition assays
Competition assay I: EV samples obtained from 2 mL plasma (yielding ~60 μg protein) and 
isolated by SEC as described above were resuspended in PBS or 100 µg/mL Tf-TR and 
incubated overnight with continuous shaking at room temperature. The incubated samples 
were ultracentrifuged twice at 100,000 x g during 70 min at 4 °C to eliminate non-bound 
fluorescent protein and supernatant samples were also collected. Aliquots of samples 
incubated with Tf-TR were incubated with a high concentration of 400 µg/mL non-
fluorescent human aTf overnight with continuous shaking at room temperature. After 
incubation, samples were ultracentrifuged twice again and a supernatant sample was 
collected. The remaining pellet was resuspended in RIPA and fluorescence was measured in a 
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Competition assay II: EV samples obtained from 2 mL plasma per condition and isolated by 
SEC as described above were resuspended in PBS or 400 µg/mL both native and denatured Tf 
and incubated overnight with continuous shaking at room temperature. The incubated samples 
were ultracentrifuged twice at 100,000 x g during 70 min at 4 °C to eliminate non-bound 
protein and supernatant samples were also collected. Aliquots of samples incubated with Tf 
were incubated with a low-concentration of 100 µg/mL Tf-TR overnight with continuous 
shaking at room temperature. After incubation, samples were ultracentrifuged twice again and 
the supernatant sample was collected. The remaining pellet was resuspended in RIPA and 
fluorescence was measured in a Perkin Elmer LS55 fluorometer (Perkin Elmer Ltd.).
2.10.2 Incubation of EVs with different Tf-TR concentrations
EV samples obtained from 2 mL plasma per condition and isolated by SEC as described 
above were resuspended in PBS, different Tf-TR concentrations (10, 20, 100, 200 μg/mL) 
and incubated overnight with continuous shaking at room temperature. The incubated 
samples were ultracentrifuged twice at 100,000 x g during 70 min at 4 °C to eliminate non-
bound protein and supernatant samples were also collected. The remaining pellet was 
resuspended in RIPA and fluorescence was measured in a Perkin Elmer LS55 fluorometer 
(Perkin Elmer Ltd.).
2.10.3 Incubation of TF-TR with different amounts of EVs
EV samples obtained from 2 mL plasma per condition were isolated by SEC as described 
above. Different amounts of EVs (30, 60, 90, 120 μg) were resuspended in PBS or 100 
μg/mL Tf-TR overnight with continuous shaking at room temperature. The incubated 
samples were ultracentrifuged twice at 100,000 x g during 70 min at 4 °C to eliminate non-
bound fluorescent protein and supernatant samples were also collected. The remaining 
pellet was resuspended in RIPA and fluorescence was measured in a Perkin Elmer LS55 
fluorometer (Perkin Elmer Ltd.).
2.11. Statistical analysis
Graph-Pad Prism 7 software was used for data analysis. Results are presented as the mean of 
at least three independent EV isolation experiments ± standard error of the mean (SEM). 
Normality of data was evaluated using Shapiro-Wilk normality test. No data points were 
excluded from the analysis. Comparisons were performed using unpaired one tailed Student’s 










where appropriate. A P value under 0.05 was considered statistically significant.
This article is protected by copyright. All rights reserved
Results
Isolation and characterization of EVs from plasma, cell lines and cell culture isolated cells
Using different strategies, we characterized EVs isolated from both human and mouse 
fluids and different conditioned media. The main objective of the isolation and 
characterization process was to obtain EVs which function properly as nanovehicles, 
focusing on EV identity, yields, quality, purity and structural integrity.
For the isolation of fluids, protocols based on differential centrifugation can result in the 
co-isolation of complexes associated with non-vesicular materials. In order to overcome 
this obstacle, we isolated vesicles from plasma using SEC in order to efficiently separate 
the vesicular fractions from the protein fractions. The amount of protein from the plasma 
fractions measured and each fraction was analyzed by Western blot to detect the typical 
CD63 marker of the vesicular route (Fig 1A).
We found that fractions 2-4 expressed CD63 and succeeded in separating the vesicular 
fraction from protein content, especially albumin. For all sources, we determined the 
identity of the vesicles by Western blot (Fig 1B) using the Alix endosomal pathway marker 
and observed a significant enrichment in the vesicular fractions with respect to plasma or 
the respective cell lysates of each source. Particularly, in EVs from in vitro secretory cells, 
the level of Alix enrichment was high. Simultaneously, we conducted analyses of proteins 
which should be absent in EVs and which are associated with compartments other than 
plasma membrane or endosomes, such as the intracellular endoplasmic protein CNX. The 
presence of CNX in the EV fraction is also an indicator of cell lysis, a condition in which 
EVs should not be isolated not only because of the contaminating components from other 
intracellular compartments, but also because of the physiological state of the cells. In this 
sense, we observed the absence of CNX in the fractions corresponding to the EVs.
It should be highlighted that, when cultured with DMEM/F12 with FCS without EVs, 
N20.1 cells were non-viable either at proliferating or differentiating temperatures. 
Moreover, EV depletion from FCS affected cell phenotype and viability especially when 
cells were grown at a non-permissive 39 °C, which indicates that serum EVs contain 
fundamental information for the development of this cell line (data not shown). Further 
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In addition, the amount of EVs produced can vary significantly depending on cell types and 
physiological state. In the current work, the yield of EV as total protein content obtained 
from the different cell lines was significantly larger than that of astrocyte cultures. Human 
and mouse plasma yielded similar amounts of EVs, in both cases higher than those obtained 
from cell lines (Table I).
We also confirmed the quality, purity and integrity of the samples through DLS and SEM. 
Worth pointing out, factors such as EV dilution of work and temperature can critically affect 
their quality as nanovehicles. On the one hand, at high concentrations and at temperatures 
over 4 °C, EVs tended to agglomerate and became difficult to handle. On the other hand, 
frozen samples stored at -80 ºC for more than 6 months and then thawed rendered 
measurements outside the expected EV hydrodynamic diameter, which indicates possible 
breakage and agglomeration due to the freezing and thawing processes (data not shown). In 
contrast, freshly isolated EVs displayed lower Z-average sizes at 4 °C (115-211 nm) than at 
25 °C (161-374 nm) in all cases, a tendency replicated by Dh. The PDI values were found to 
be between 0.237 and 0.381 for monomodal EVs and between 0.427 and 0.554 for bimodal 
samples at 25 °C. Also, monomodal size distribution indicated the existence of a single 
population in the range of sizes expected for EVs, thus ruling out the presence of 
contaminating residues from the isolation process or EV agglomeration. Moreover, Z-average 
sizes for Tf-free EVs and Tf-loaded EVs derived from human plasma were 161 and 267 nm at 
25 °C, respectively. Worth highlighting, Tf incorporation on the surface of EVs did not 
significantly affect the range of sizes found for EVs and actually rendered a lower negative Z-
potential (-36 mV) than Tf-free EVs (-27 mV). The average Z-potential of free Tf at a charge 
concentration identical to that used for the formation of Tf-loaded EVs was approximately -14 
(±2) mV (Table II and IV and Fig 2).
Finally, SEM revealed uncompromised integrity of the vesicle structures obtained through the 
two isolation methods and determined the heterogeneity of EV sizes within each source and 
their average (Fig 3). Of note, even though the EV sources used in this study are 
morphologically heterogeneous, their EVs had comparable sizes and shapes (Fig 3).
Altogether, these results confirm the successful isolation of EVs from very different and 
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EV expression of TfR1 and loading with aTf
Previous studies demonstrated that TfR1 is released in association to vesicles (Pan et al., 
1983). Indeed, electron microscopic studies have shown that endocytosis of TfR1 is 
followed by the formation of multivesicular bodies which, upon fusion with the plasma 
membrane, release 50 nm buds into the extracellular milieu. TfR1 released in vesicular 
form is apparently unchanged in its molecular weight, peptide sequence and capacity for 
aTf binding (Pan et al., 1985). In agreement with this evidence, all EVs isolated from 
different conditioned media in the current study showed the presence of TfR1 (Fig 4 and 
Table III), which exhibited 90 kDa, the size expected for an intact, still membrane-
associated monomer. In addition, immunoblotting assays on 1 mL fractions obtained from 
SEC confirmed TfR1 association to EVs, in agreement with the colocalization of CD63 and 
TfR1 in fractions 2-4 (Fig 1A).
Based on these findings, we analyzed the ability of EVs to load our protein of interest, aTf.
Western blot analyses revealed aTf presence both in EVs isolated from human plasma 
incubated with aTf and in those secreted by aTf-treated OLN-93 cells, while no aTf 
expression was observed in control human plasma EVs or in vehicle-treated cells (Fig. 4A 
and B).
In turn, EVs incubation with Tf-TR showed higher fluorescence intensity than controls and 
rendered around 330 ng/mg EVs. In contrast, EV-free PBS incubated with Tf-TR and 
subsequently processed as EV-containing samples exhibited no fluorescence, which 
indicates that Tf binding requires the presence of EVs. These results, obtained by means of 
two different methodologies, indicate that EVs isolated from different sources were able to 
bind aTf (Fig 4C).
Two different competition assays were conducted to determine whether the binding of Tf to 
EVs proceeded through its interaction with TfR1 located at the extraluminal phase of the 
EVs and also whether this interaction was specifically due to the binding of Tf-TR to TfR1. 
In the first competition assay, EVs showed lower fluorescence intensity values, indicating 
that bound Tf-TR was displaced by the excess of non-labeled Tf. The low remnant signal 
detected may indicate a minimal diffusion into EVs along the concentration gradient (Fig 
5A, B). The second competition assay showed that saturating concentrations of native non-
labeled aTf occupied all TfR1 binding sites in the EVs, whereas subsequent incubation with 
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turn, saturating concentrations of denatured non-labeled aTf followed by incubation with 
low concentrations of labeled Tf-TR did reveal fluorescence signal regarding controls. 
These findings indicate that the loading of Tf into EVs occurred through the specific 
binding of Tf-TR to its receptor TfR1 in the extraluminal phase of EVs (Fig 5C, D). In 
addition, when the amount of EVs in the samples varied between 30 and 120 g, the 
amount of Tf-TR remained fairly constant, as indicated by the similarity of EV 
fluorescence across samples. Moreover, when the concentration of Tf-TR in the samples 
varied but the amount of EVs in the samples was kept constant, the fluorescence ratio also 
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Discussion
Tf is a glycoprotein synthesized mostly in the liver. The main function of Tf is to capture Fe3+ 
released into plasma from intestinal enterocytes or reticuloendothelial macrophages, maintain 
Fe3+ in a redox-inert state, and deliver it into tissues (Anderson et al., 2009). The binding of 
iron-laden Tf to cell-surface TfR1 results in endocytosis and uptake of the metal cargo. In the 
CNS, most Tf is synthesized endogenously by oligodendrocytes and choroid plexus cells, and 
it is required for iron mobilization within the brain parenchyma and CSF (Espinosa de los 
Monteros et al., 1988). In our laboratory, we have demonstrated that aTf can increase cell 
proliferation in the subventricular zone and promote oligodendrocyte lineage commitment and 
terminal maturation (Silvestroff et al., 2012). Furthermore, we also reported that a single 
intracranial injection of aTf prevents hypomyelination produced by iron deficiency in rats 
(Badaracco et al., 2008). Collectively, these findings allowed us to define aTf as a trophic 
factor for the CNS. However, the intracranial injection of aTf might not be practical for 
clinical treatments, a drawback which requires the development of less invasive techniques 
capable of delivering aTf to the CNS.
In this sense, the intranasal route emerges as a promising non-invasive way to deliver 
molecules to the brain as it has many advantages from a clinical point of view; that is, 
molecules at biologically effective concentrations or even living cells can bypass the BBB and 
enter the CNS directly, avoiding hepatic and intestinal metabolism without serious systemic 
side effects (Thorne et al., 2001; Merkus et al., 2007; Danielyan et al., 2009). We have 
demonstrated in a rat model of hypoxia-ischemia encephalopathy that intranasally 
administered radio-labeled aTf can reach distant areas of the CNS, decreasing astrogliosis and 
neuronal loss, and promoting the survival and maturation of oligodendroglial precursors after 
demyelination (Guardia Clausi et al., 2012), which suggests intranasal aTf potential to induce 
remyelination.
EVs have recently risen to stardom as an excellent delivery system due to their distribution 
over long distances, long circulation half-life and reduced toxicity (Mathieu et al., 2011; Lai et 
al., 2013; Tan et al., 2013). Several features place EVs as potentially powerful shuttles for the 
delivery of therapeutic agents to the brain (Aryani et al., 2016). EVs loaded with antioxidant 
catalase given by intranasal administration have provided significant neuroprotection in an 









This article is protected by copyright. All rights reserved
also been administered intranasally in mice, decreasing LPS-induced brain inflammation 
(Zhuang et al., 2011).
Although EVs show several advantages over other nanoparticle systems for carrying 
therapeutically active molecules, particularly polymer-based nanoparticles and lipid-based 
systems (Rufino-Ramos et al., 2017), EV isolation and purification methods still pose a 
challenge and should be improved to render higher yields, which will allow large-scale 
production and wide-spread use in clinical practice.
In this study, we isolated and properly characterized EVs from human and mouse plasma, rat 
oligodendroglioma cells OLN93, mouse neuroblastoma cells N2a and rat astrocytes in 
primary cultures, all of them expressing TfR1 and thus potentially capable of delivering aTf to 
the CNS. TfR1 plays a central role in the transport of iron from the iron-Tf complex into the 
cell, which makes it ubiquitous in growing cells owing presumably to iron requirements for 
proliferation (Wang et al., 2011). There is general agreement that TfR1 undergoes 
internalization during iron delivery, and that Tf and its receptor are recycled back to the 
plasma membrane without degradation during many delivery cycles (Mellman et al., 1996). 
Furthermore, TfR1 is externalized by evagination of the plasma membrane in the form of EVs 
(Pan et al., 1983). Although studies in analog human cell lines had reported the presence of 
TfR1 in neuroblastoma- and astrocytoma-derived EVs (Marimpietri et al., 2013; Choi et al., 
2018), in this work we demonstrate for the first time the expression of TfR1 in EVs derived 
from OLN93, N2a cells and astrocytes.
EV yields depend on cell types and lines. Primary cultures are known to secrete fewer EVs 
than cell lines (Taylor et al., 2008; Logozzi et al., 2009), though the reason for this is not fully 
understood. We found that OLN93 and N2a cells rendered EV yields similar to those reported 
by El-Andaloussi et al. (El-Andaloussi et al., 2012) in HEK cells, and significantly higher than 
astrocyte cultures. This is in agreement with the fact that normal cells usually secrete fewer 
signal molecules through their vesicles than transformed cells. Plasma, on the other hand, 
yielded the largest amount of EVs, probably due to the contribution of other circulating cell 
types.
In agreement with literary evidence (Park et al., 2010), EV samples revealed the expression of 
characteristic proteins tetraspanin CD63 and intraluminal protein Alix and, as expected, 
showed the absence of endoplasmic reticulum protein CNX. In addition, EV Z-average sizes 
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In turn, PDI is an indicator of the degree of aggregation and size distribution of samples and is 
usually acceptable below 0.5. In this sense, PDI values were acceptable for all monomodal 
samples and their ranges were consistent with those previously reported by other authors 
(Sokolova et al., 2011). In addition, the size distribution analyzed was within the range 
expected for EVs from other sources, and larger EVs were not visualized. However, we 
detected smaller vesicles, especially when EVs were obtained from cell lines, which were 
probably cell-released ectosomes. This result indicates that both methods of isolation yielded 
EVs matching the EV size range and lacking significant impurities associated to larger EVs. 
Z-potential is an estimation of surface charge registered for unloaded or loaded nanoparticles, 
and it is usually a predictive tool of colloidal stability at 25 °C. Nanoparticles with Z-potential 
values greater than +25 mV or less than -25 mV typically have high degrees of stability, whereas 
dispersions with a low Z-potential absolute value and close to neutrality will eventually 
aggregate due to Van Der Waal interparticle attractions (Blachman et al., 2020). In this context, 
the fact that Tf incorporation did not significantly affect the range of EV sizes and even 
displayed a lower negative average Z-potential than that of Tf-free EVs suggests, first, the 
successful surface modification of these vesicles with Tf and, second, the great stability of this 
system as a potential biological nanocarrier.
SEM in turn revealed the structural integrity of EVs but also the size heterogeneity of each 
population and the purity obtained by both methods. First, the spherical morphology of EVs 
reflected their structural integrity and sizes were moderately smaller than those determined by 
DLS, especially for astrocytes and mouse plasma sources. These findings suggest changes in 
contraction patterns during sample preparations for SEM, while hydration sphere phenomena 
should not be ruled out for samples determined by DLS (Sokolova et al., 2011). Overall, this set 
of biochemical and biophysical properties will allow to attribute cargo-loading functions to EVs 
isolated from different sources. 
Regarding the route underlying Tf binding, competition assays were carried out on the basis of 
the following hypothesis: if binding is non-specific to TfR1, both native and denatured protein 
will be adsorbed nonspecifically by the vesicular surface; on the other hand, if Tf binding is 
specific to TfR1, native Tf will saturate all TfR1 binding sites and will not be displaced upon 
incubation with Tf-TR at lower concentrations, whereas denatured Tf, in lacking the three-
dimension conformation necessary to bind to the receptor and thus being unable to compete with 
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Most interestingly, these assays allowed to verify that a) Tf binding took place in the 
extraluminal phase of EVs, b) Tf was incorporated into EVs specifically through binding to 
TfR1, and c) all Tf binding sites were occupied upon EV incubation. 
Altogether, the results obtained suggest that EVs isolated from different sources containing TfR1 
can incorporate Tf by two distinct approaches of passive loading. To sum up, EVs have become 
increasingly relevant due to their function in intercellular communication and a wide range of 
physiological, pathological and therapeutic roles. Although further studies are in progress to 
track Tf-loaded EVs and ultimately determine whether they reach oligodendroglial cells in a 
demyelinating model, the current results pave the way for their potential clinical use as 
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Figure legends
Figure 1. Determination of the vesicular fraction in plasma samples and characterization of 
EV sources by immunoblotting. A) Protein absorbance measurements (280 nm) of each plasma 
sample. SEC fraction and immunoblot analysis of CD63 EV marker of each SEC fraction 
colocalizing with TfR1. B) Immunoblot analysis of CD63, Alix and CNX in EV samples, plasma 
and cell lysates. n = 3 (independent plasma or conditioned media preparations).
Figure 2. Size distribution of different EV sources by DLS. Z-average size for particle 
suspension at 4 ºC and 25 ºC. n = 2 (independent plasma or conditioned media preparations). 
Results are presented as the mean of two independent experiments ± standard deviation (SD). A) 
Human plasma EVs, B) mouse plasma EVs, C) N2a EVs, D) OLN-93 EVs, E) astrocyte primary 
culture EVs.
Figure 3. Morphological analysis of different EV sources by SEM. After ultracentrifugation, 
the pellets of all samples were resuspended in 50 μl PFA 4% during 15 minutes at 4º, washed 
with 1 ml of MilliQ water and ultracentrifuged again at 100,000 x g 70 min. The resulting pellet 
was resuspended in 50 μl of Milli-Q wáter and, after metalized, Twenty µL of fresh samples 
were put on a silica substrate, dried, metalized and observed with a Zeiss Supra Electron 
microscope. n = 2 (independent plasma or conditioned media preparations). Six fields were 
chosen randomly per n, and EV size was determined calculating first the area of each individual 
EV to obtain the diameter. Results are presented as the mean of two independent experiments ± 
standard deviation (SD). A) Human plasma EVs and frequency of sizes, B) mouse plasma EVs 
frequency of sizes, C) N2a EVs and frequency of sizes, D) OLN-93 EVs and frequency of sizes, 
E) astrocyte primary culture EVs and frequency of sizes. F) Average diameter  from different 
EV sources. Scale bar: 100 nm
Figure 4. TfR1 detection in different EV sources and passive loading of Tf by two loading 
strategies. A) Immunoblot analysis of TfR1 in different EV sources. B) Schematic 
representation of passive cargo loading of aTf into OLN-93 EVs. OLN93 cells were incubated in 
the presence of 100 µg/mL aTf for 30 min at 37 °C. After incubation, EVs were isolated by 
differential centrifugation and ultracentrifugation and aTf incorporation was verified by Western 
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human plasma by SEC were incubated with 100 μg/mL of aTf overnight at room temperature 
and loading efficiency was evaluated by Western blot. (2) EVs isolated from 2 mL of human 
plasma by SEC were incubated with 100 μg/mL of Tf-TR overnight in agitation at room 
temperature. Ratio was calculated by using RFU values: EVs-Tf ratio: EV-Tf/(Tf+UC1-2). n = 4 
(independent plasma preparations).  Comparisons were performed using Student’s t test (*P < 
0.05; **P <0.01; ***P < 0.001 ****p< <0,0001). Results are presented as the mean of at least 
three independent experiments ± standard error of the mean (SEM). 
Figure 5. Tf binding competition assays. A) Schematic representation of Competition assay I: 
equal masses of EVs were incubated with PBS or PBS +100 μg/μl Tf-TR overnight in agitation 
at room temperature. The next day, samples were washed and ultracentrifuged in order to wash 
the remaining non-bound fluorescent Tf and the pellets were then incubated with non-fluorescent 
400 μg/μl aTf in order to evaluate the displacement of fluorescent protein binding. Incubation 
and isolation conditions were those described above. Finally, the pellets obtained were 
resuspended in 20 μl RIPA buffer and samples were analyzed by fluorometry. B) Ratio was 
calculated by using RFU’s values: EVs-Tf ratio: EV-Tf/(Tf+UC1-2). n = 4 (independent plasma 
preparations). Comparisons were performed using Student’s t test (*P < 0.05; **P <0.01; ***P < 
0.001 ****p< <0,0001). Results are presented as the mean of at least three independent 
experiments ± standard error of the mean (SEM). C) Schematic representation of Competition 
assay II: EVs were incubated with with non-labeled Tf in its native conformation and denatured 
Tf at a saturating concentration (400 µg/mL) and then incubated with a 4-time lower 
concentration of Tf-TR with (100 µg/mL). Procedures were the same as in A). n = 4 
(independent plasma preparations). Comparisons were performed using one way ANOVA 
followed by Bonferroni post hoc test (*P < 0.05; **P <0.01; ***P < 0.001). E) Ligand-receptor 
binding assay using different amounts of EVs (30, 60, 90 and 120 μg) and 100 μg/mL of Tf-TR. 
n = 4 (independent plasma preparations). F) Ligand-receptor binding assay using different 




























  Astrocyte primary 
         
culture                  
                 
  Cellular density   
5.105 cells/mL 
   
6,2.105 cells/mL 
   
6,2.105 cells/mL 
   
2,0.105 cells/mL 
 
               
  (cells/mL of CM)                 
                   
    
          
 
 Conditioned medium volume  40 mL   40 mL   80 mL   80 mL 
              
 Protein Concentration   1-4 µg/µL    1-2 µg/µL    1-2.5 µg/mL    0,5-0.7 µg/µL  
                             
                   
    
             
 







25  µg   
resuspension volume 
       
                 
               
     EVs Source    Human plasma    Mouse plasma      
                   
  
             
 
    Plasma volume   4 mL   4 mL     
                   
                  
    Protein    
1-2 µg/µL 
   
1-3 µg/µL 
     
     
concentration 
           
                  
                  
  
               
 
    Total protein in             
    RIPA’s resuspension   120 µg   150 µg     
    volume             




Table II. Dynamic light scattering (DLS) of EVs derived from human and mouse plasma (Hp 




                     *Major population 






















4 115 (7) 163 (19) 100 (0) -- -- 0.240 (0.027) 
25 161 (7) 179 (5) 100 (0) -- -- 0.299 (0.038) 
Mp 
4 190 (4) 192 (6) 100 (0) -- -- 0.238 (0.022) 
25 200 (5) 208 (11) 100 (0) -- -- 0.248 (0.013) 
N2a 
4 157 (14) 167 (24) 100 (0) -- -- 0.287 (0.045) 
25 202 (4) 239 (52) 100 (0) -- -- 0.381 (0.028) 
OLN-93 
4 166 (9) 182 (19) 100 (0) -- -- 0.269 (0.063) 
25 180 (5) 196 (7) 100 (0) -- -- 0.237 (0.020) 
Astrocyte  
primary culture 
4 211 (14) 256 (22) 100 (0) -- -- 0.331 (0.049) 




Table III. Bibliographic compilation from Exocarta’s database containing sources, species and 
reference of vesicles containing TfR1 and our contribution in this paper. 
 
     Homo sapiens  Mus musculus  Rattus norvegicus 
                   
 Gene    Vesicle  Vesiclepedia  Vesicle  Vesiclepedia  Vesicle  Vesiclepedia 
 Symbol/ 
Vesicle 
Source  Type  Reference  Type  Reference  Type  Reference 
 Protein                  
                   
 CD71/TfR1       Plasma   Exosome  15908444   
Exosom
e  22046311   -  -  
                   
     Exosome 24115447   EVs  This study - -  
                  
     Microsome  21049385            
                   
     Microsome 23056467            
                  
     EVs  This study            
                   
     Exosome/ 24069378   EVs  This study - -  
  Neuroblastoma  Membrane              
     vesicle              
             
  
Oligodendro-
glioma   -  -   -  -   EVs  This study  
                   
     Astrocynoma 30006486  - -   EVs   This study 
  Astrocytes  cells EVs              




Table IV. Z-average size, hydrodynamic diameter (Dh), size distribution (PDI) and Z-potential of Tf-free  























161 (7) 179 (5) 100 (0) -- 
-- 
0.299 (0.038) -27 (4) 
 
Hp/Tf EV 267 (4) 253 (53) 89 (4) 43 (18) 11 (4) 0.427 (0.065) -36 (2) 





